RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Antibody-Drug combo aims to tackle tough leukemia
Disease control Recruiting nowThis study is testing a drug called inotuzumab ozogamicin, which is like a smart bomb that targets and kills leukemia cells, combined with low-intensity chemotherapy. The goal is to find the best dose and see if this combo works better than standard treatments for patients with a…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to outsmart relapsed leukemia in kids
Disease control Recruiting nowThis phase 2 trial is testing whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) with relapsed B-cell acute lymphoblastic leukemia (B-ALL), including those with Down syndrome. Blinatumomab helps the immune system find and kill cancer cells, wh…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a pill make CAR T-Cell therapy last longer?
Disease control Recruiting nowThis early-phase trial tests whether the drug pomalidomide can improve the effects of CAR T-cell therapy in people with B-cell leukemias or lymphomas that have returned or not responded to treatment. The study will enroll 12 adults who have already received CAR T-cell therapy. Re…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kids with tough leukemia: targeted Antibody-Drug combo shows promise
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin in children and young adults (ages 1 to 21) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard treatment. The drug works like a guided missile, attaching to a marker (CD22) on cancer cel…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Dual-Target CAR t therapy hopes to beat childhood leukemia
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD19 and CD22, on leukemia cells. It is for children and young adults up to age 21 whose leukemia has returned or not responded to standard treatments. The main goal is to find…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for hard-to-treat leukemia: triple drug combo enters human testing
Disease control Recruiting nowThis early-phase trial tests whether combining three drugs (recombinant Erwinia asparaginase, venetoclax, and blinatumomab) is safe and effective for adults whose B-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. The study enrolls 26 people age…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC